April 28, 2022
Opioid/Substance Use Disorders
  • Members of the House Oversight and Reform Committee questioned McKinsey & Company about its potential role in exacerbating the opioid epidemic. The hearing comes after the committee released a report alleging a years-long conflict of interest stemming from McKinsey’s consulting work with federal agencies, which occurred at the same time it was working with pharmaceutical companies. McKinsey’s global managing partner Bob Sternfels adamantly denied the accusation in the report and said that the firm’s work with opioid companies “fell short of our standards, and it’s why we pivoted to settle with the states and spend over $575 million on prevention and treatment. So we’re all in and being part of the solution going forward.” (Articles here, here, and here)